2025
Lipid Peroxidation and Glutathione Levels Among People Living With HIV Co‐infected With Human Coronaviruses in Ghana
Amegashie E, Kwayisi‐Darkwah C, Adusei‐Poku M, Sikeola R, Ativi L, Ahene A, Atampugbire G, Tagoe E, Paintsil E, Torpey K, Quaye O. Lipid Peroxidation and Glutathione Levels Among People Living With HIV Co‐infected With Human Coronaviruses in Ghana. Journal Of Medical Virology 2025, 97: e70301. PMID: 40110873, DOI: 10.1002/jmv.70301.Peer-Reviewed Original ResearchMeSH KeywordsAdultCoinfectionCoronavirus InfectionsCross-Sectional StudiesCyclopropanesDideoxyadenosineDideoxynucleosidesFemaleGhanaGlutathioneHeterocyclic Compounds, 3-RingHIV InfectionsHumansLipid PeroxidationMaleMalondialdehydeMiddle AgedOxazinesOxidative StressPiperazinesProspective StudiesPyridonesYoung AdultConceptsHuman immunodeficiency virusHuman immunodeficiency virus co-infectionCo-infectionGSH levelsART-experienced individualsPLWH co-infectedHuman coronavirusesHIV co-infectionHIV-negative individualsMalondialdehyde levelsOxidative stressOxidative stress markersIncreased MDA levelsCross-sectional studyOro-pharyngeal swabsImmunodeficiency virusGhanaian patientsMono-infectionReduced GSH levelsTreatment strategiesPlasma samplesDisease severityMDA levelsStress markersTailored monitoringAn atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis
El Bounkari O, Zan C, Yang B, Ebert S, Wagner J, Bugar E, Kramer N, Bourilhon P, Kontos C, Zarwel M, Sinitski D, Milic J, Jansen Y, Kempf W, Sachs N, Maegdefessel L, Ji H, Gokce O, Riols F, Haid M, Gerra S, Hoffmann A, Brandhofer M, Avdic M, Bucala R, Megens R, Willemsen N, Messerer D, Schulz C, Bartelt A, Harm T, Rath D, Döring Y, Gawaz M, Weber C, Kapurniotu A, Bernhagen J. An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis. Nature Communications 2025, 16: 2297. PMID: 40055309, DOI: 10.1038/s41467-025-57540-z.Peer-Reviewed Original ResearchConceptsApoE-/- miceHyperlipidemic apoE-/- miceCoronary artery diseaseDecreased plasma lipid levelsPlasma lipid levelsHepatic lipid accumulationAtherogenic chemokinesFoam-cell formationFLIM-FRET microscopyArtery diseasePlasma concentrationsVascular inflammationInflammatory conditionsMetabolic dysfunctionAtherosclerotic patientsLipid accumulationAdvanced atherosclerosisMyocardial infarctionLipid levelsSuppressed hepatic lipid accumulationAdvanced atherogenesisCarotid plaquesDisease severityIschemic strokeChemokinesEstimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
Xu H, Aparicio C, Wats A, Araujo B, Pitzer V, Warren J, Shapiro E, Niccolai L, Weinberger D, Oliveira C. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Network Open 2025, 8: e250380. PMID: 40063022, PMCID: PMC11894488, DOI: 10.1001/jamanetworkopen.2025.0380.Peer-Reviewed Original ResearchConceptsRSV-positive casesCase-control studyRSV infectionLRTI-associated hospitalizationsWeeks postimmunizationLong-acting monoclonal antibodiesTest-negative case-control studyClinical settingRespiratory syncytial virusMultivariate logistic regressionYale New Haven Health SystemRSV diseaseEmergency department dataState immunization registryRSV seasonSyncytial virusNirsevimabPolymerase chain reactionClinical trialsLRTIInfantsPotential confoundersMonoclonal antibodiesBroader outcomesDisease severityImpact of disease severity, age, sex, comorbidity, and vaccination on secondary attack rates of SARS-CoV-2: a global systematic review and meta-analysis
Sumsuzzman D, Ye Y, Wang Z, Pandey A, Langley J, Galvani A, Moghadas S. Impact of disease severity, age, sex, comorbidity, and vaccination on secondary attack rates of SARS-CoV-2: a global systematic review and meta-analysis. BMC Infectious Diseases 2025, 25: 215. PMID: 39948450, PMCID: PMC11827239, DOI: 10.1186/s12879-025-10610-5.Peer-Reviewed Original ResearchConceptsPopulation settingEffective public health strategiesConfidence intervalsImpact of disease severityModified Newcastle-Ottawa ScalePublic health strategiesHigher secondary attack rateRisk of biasNewcastle-Ottawa ScalePandemic responseGlobal systematic reviewRandom-effects modelFreeman-Tukey double arcsine transformationWeb of ScienceNo significant associationDrivers of SARS-CoV-2 transmissionHealth strategiesSecondary attack rateSARS-CoV-2Disease severityEffective pandemic responseTargeted interventionsDouble arcsine transformationOvid MEDLINESystematic reviewPreliminary Evidence for Perturbation‐Based tACS‐EEG Biomarkers of Gamma Activity in Alzheimer's Disease
Palmisano A, Pezanko L, Cappon D, Tatti E, Macone J, Koch G, Smeralda C, Romanella S, Ruffini G, Rivolta D, Press D, Pascual‐Leone A, El‐Fakhri G, Santarnecchi E. Preliminary Evidence for Perturbation‐Based tACS‐EEG Biomarkers of Gamma Activity in Alzheimer's Disease. International Journal Of Geriatric Psychiatry 2025, 40: e70025. PMID: 39799469, DOI: 10.1002/gps.70025.Peer-Reviewed Original ResearchConceptsPeripheral neuroinflammationIdentification of novel biomarkersResponse to TACPatient's clinical phenotypeSpectral powerGABAergic dysfunctionNo significant correlationPrognostic valueInhibitory circuitryClinical severityClinical phenotypeAnimal modelsCognitive statusNeuroinflammatory markersAlzheimer's diseaseHuman patientsNeuroinflammatory biomarkersNovel biomarkersPatientsDisease severityTherapeutic targetGamma activityBiomarkersMild to moderate dementiaSignificant correlation
2024
Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy
Meisner J, Renberg A, Smith E, Tsan Y, Elder B, Bullard A, Merritt O, Zheng S, Lakdawala N, Owens A, Ryan T, Miller E, Rossano J, Lin K, Claggett B, Ashley E, Michels M, Lampert R, Stendahl J, Abrams D, Semsarian C, Parikh V, Wheeler M, Ingles J, Olivotto I, Day S, Saberi S, Russell M, Previs M, Ho C, Ware J, Helms A. Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy. Circulation 2024, 151: 783-798. PMID: 39633578, PMCID: PMC11913586, DOI: 10.1161/circulationaha.124.069398.Peer-Reviewed Original ResearchPathogenic sarcomeric variantsOvert hypertrophic cardiomyopathySarcomere variantsHypertrophic cardiomyopathyGeneral populationSarcomeric genesCardiac magnetic resonance imaging analysisSarcomeric Human Cardiomyopathy RegistryInduced pluripotent stem cell-derived cardiomyocytesPluripotent stem cell-derived cardiomyocytesStem cell-derived cardiomyocytesAssociated with disease severityDisease severityCardiac magnetic resonance imaging dataCell-derived cardiomyocytesMagnetic resonance imaging analysisMild hypertrophic cardiomyopathyIncreased disease severityCardiomyopathy RegistryDisease riskClinical outcomesAdverse eventsSignificant additive effectsEffect sizePolygenic contributionBenefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study
Lewis N, Harker E, Grant L, Zhu Y, Grijalva C, Chappell J, Rhoads J, Baughman A, Casey J, Blair P, Jones I, Johnson C, Lauring A, Gaglani M, Ghamande S, Columbus C, Steingrub J, Shapiro N, Duggal A, Busse L, Felzer J, Prekker M, Peltan I, Brown S, Hager D, Gong M, Mohamed A, Exline M, Khan A, Hough C, Wilson J, Mosier J, Qadir N, Chang S, Ginde A, Martinez A, Mohr N, Mallow C, Harris E, Johnson N, Srinivasan V, Gibbs K, Kwon J, Vaughn I, Ramesh M, Safdar B, Goyal A, DeLamielleure L, DeCuir J, Surie D, Dawood F, Tenforde M, Uyeki T, Garg S, Ellington S, Self W, Gaglani M, McNeal T, Calhoun S, Murthy K, Cravens J, Herrick J, McKillop A, Hoffman E, Graves A, Zayed M, Smith M, Gaglani M, Columbus C, Bychkowski A, Dunkley S, Fisher T, Grefsrud T, Hurutado-Rodriguez M, Perez G, Busse L, Lohuis C, Felzer J, Prekker M, Hendrickson A, Frosch A, Taghizadeh L, Hurreh K, O'Rourke M, Giles L, Vaughn I, Ramesh M, Lamerato L, Almawri K, Atkins I, Clark J, Lava J, McKeon C, Pinderi Z, Resk M, Koneru S, Jayaprakash R, Tirumala S, Williams K, Peltan I, Lumpkin J, Poulson S, Bassett J, Thumma V, Hager D, Ali H, Richard, Saeed S, Mohr N, Zepeski A, Nassar P, Hampton J, Fairfield C, Gibbs H, Feitsam C, Appleton I, Gong M, Mohamed A, Andrea L, Exline M, Karow S, Swoope G, So M, Pathak M, Smith D, Wilson R, Lewald Z, Snyder C, Khan M, Lee B, Rasul A, Khan A, Hernandez-Frausto A, Pocius E, Tribbett E, Briceno G, Pena J, Pellicer S, Reddy R, Allada G, Wilson J, Gordon A, Perez C, Lau L, Ferguson S, Pitre V, Tam G, Basobas L, Mosier J, Lutrick K, Hypes C, Campbell B, Ginde A, Martinez A, Steinwand A, Sullivan A, Withers C, Rademacher J, Obradovich R, Mallow C, Rivas C, Johnson N, Acidera J, Elkort K, Gajendragadkar A, McKeown M, Self W, Talbot H, Grijalva C, Blair P, Jones I, Halasa N, Chappell J, Womack K, Rhoads J, Ratcliff C, Baughman A, Johnson J, Swan S, Johnson C, Zhu Y, Rice T, Casey J, Zhu Y, Short L, Ezzell L, Whitsett M, McHenry R, Hargrave S, Luther J, Pulido C, Peterson B, Cummings S, Gauthier E, Jackson A, Rashid N, Blair M, Rice C, Kwon J, Parikh B, McDonald D, Samuels C, Vogt L, O'Neil C, Valencia A, Yerbic F, Arter O, Vu K, Safdar B, Goyal A, DeLamielleure L, Kosover M. Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study. Clinical Infectious Diseases 2024, ciae584. PMID: 39607747, DOI: 10.1093/cid/ciae584.Peer-Reviewed Original ResearchDays of hospital admissionPulmonary disease severityKidney replacement therapyIn-hospital deathIntensive care unitDay of admissionOseltamivir treatmentVasopressor useReplacement therapyInitiation of antiviral therapyOdds of intensive care unit admissionAcute kidney replacement therapyExtrapulmonary organ failureInfluenza-positive patientsLaboratory-confirmed influenzaIntensive care unit admissionDisease severityHospital admissionMultivariate logistic regression modelSentinel Surveillance NetworkOseltamivir therapySuspected influenzaInfluenza AAntiviral therapyMultivariable proportional odds modelParent Perspectives on Nirsevimab for Their Newborn.
Hinderstein S, Aragona E, Loyal J. Parent Perspectives on Nirsevimab for Their Newborn. Pediatrics 2024, 154 PMID: 39587878, DOI: 10.1542/peds.2024-067532.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusRespiratory syncytial virus prophylaxisRSV disease severityMaternal RSV vaccineHealth Belief ModelHealthy newbornsRSV vaccineRSV infectionParents of newbornsNewborn unitSyncytial virusNirsevimabSide effectsNewbornsBelief ModelPediatric hospitalMonoclonal antibodiesDisease severityCOVID-19 vaccineProphylaxisVaccineIncreasing overall awarenessInfantsPediatrician's recommendationPositively influence decisionNeuroprotective effect of neuron‐specific deletion of the C16 ceramide synthetic enzymes in an animal model of multiple sclerosis
Amatruda M, Marechal D, Gacias M, Wentling M, Turpin‐Nolan S, Morstein J, Moniruzzaman M, Brüning J, Haughey N, Trauner D, Casaccia P. Neuroprotective effect of neuron‐specific deletion of the C16 ceramide synthetic enzymes in an animal model of multiple sclerosis. Glia 2024, 73: 271-290. PMID: 39489703, PMCID: PMC11662985, DOI: 10.1002/glia.24631.Peer-Reviewed Original ResearchExperimental autoimmune encephalomyelitisNeuron-specific deletionMultiple sclerosisDemyelinating disordersCourse of EAESalvage pathwayAnimal model of multiple sclerosisModel of multiple sclerosisDisease severityRecycling of sphingosineWild type miceCeramide synthase 6Central nervous systemPalmitic acidAutoimmune encephalomyelitisExposure to oxidative stressType miceInflammatory demyelinationMyelin damageSaturated fatAnimal modelsMitochondrial dysfunctionCerS5Nervous systemNeuroprotective effectsThe Association Between Patient-Reported Disease Burden and Treatment Switching in Patients with Plaque Psoriasis Treated with Nonbiologic Systemic Therapy
Patel V, Park S, Zhong Y, Sima A, Zhuo J, Roberts-Toler C, Becker B, Hovland S, Strober B. The Association Between Patient-Reported Disease Burden and Treatment Switching in Patients with Plaque Psoriasis Treated with Nonbiologic Systemic Therapy. Psoriasis Targets And Therapy 2024, 14: 167-174. PMID: 39624651, PMCID: PMC11610380, DOI: 10.2147/ptt.s478352.Peer-Reviewed Original ResearchPatient-reported disease burdenVisual analog scaleBiologic therapyPlaque psoriasisDisease burdenOdds ratioInitiation of biologic therapyQuality of lifeCorEvitas Psoriasis RegistryNonbiologic systemic therapyDisease severityPatient-reported burdenMultivariate logistic regression modelDermatology Life Quality IndexDays of enrollmentReal-world studyWork Productivity and Activity Impairment QuestionnaireLife Quality IndexPhysician-rated disease severityTherapy-naiveBiologic-naiveHealth-related quality of lifePsoriasis RegistrySystemic therapySkin painAnti-integrin αvβ6 autoantibodies are increased in PSC patients with concomitant IBD and correlate with liver disease severity
Bloemen H, Livanos A, Martins A, Dean R, Bravo A, Bourgonje A, Tankelevich M, Herb J, Cho J, Santos A, Rodrigues C, Petralia F, Colombel J, Bowlus C, Schiano T, Torres J, Levy C, Mehandru S. Anti-integrin αvβ6 autoantibodies are increased in PSC patients with concomitant IBD and correlate with liver disease severity. Clinical Gastroenterology And Hepatology 2024 PMID: 39490950, DOI: 10.1016/j.cgh.2024.10.005.Peer-Reviewed Original ResearchPrimary sclerosing cholangitis patientsPrimary sclerosing cholangitisLiver disease severityConcomitant inflammatory bowel diseaseInflammatory bowel diseaseHealthy controlsEnzyme-linked immunosorbent assayDisease severityAssociated with liver disease severityUlcerative colitisAssociated with markers of systemic inflammationMayo PSC risk scoreMarkers of systemic inflammationMarkers of liver disease severityLiver stiffness measurementMultivariate linear regression analysisAlkaline phosphatase levelsAssociated with markersInflammatory bowel disease subtypePSC patientsSclerosing cholangitisInflammation panelSystemic inflammationPSC-UCPSC-IBDSaturation mutagenesis-reinforced functional assays for disease-related genes
Ma K, Huang S, Ng K, Lake N, Joseph S, Xu J, Lek A, Ge L, Woodman K, Koczwara K, Cohen J, Ho V, O'Connor C, Brindley M, Campbell K, Lek M. Saturation mutagenesis-reinforced functional assays for disease-related genes. Cell 2024, 187: 6707-6724.e22. PMID: 39326416, PMCID: PMC11568926, DOI: 10.1016/j.cell.2024.08.047.Peer-Reviewed Original ResearchDisease-related genesDisease-causing genetic variantsGenome-wide resolutionMutation scanning methodsSingle-nucleotide variantsDeep mutational scanning methodFunctional assaysDisease genesComputational predictorsSaturation mutagenesisHuman geneticsGenetic variantsGenesVariantsSmurfAssayMutagenesisLARGE1GeneticsDisease severityDeep-learning generated B-line score mirrors clinical progression of disease for patients with heart failure
Baloescu C, Chen A, Varasteh A, Hall J, Toporek G, Patil S, McNamara R, Raju B, Moore C. Deep-learning generated B-line score mirrors clinical progression of disease for patients with heart failure. The Ultrasound Journal 2024, 16: 42. PMID: 39283362, PMCID: PMC11405569, DOI: 10.1186/s13089-024-00391-4.Peer-Reviewed Original ResearchB-line scoreComposite congestion scoreCongestion scoreHeart failureSeverity scoreB-linesCongestive heart failurePatients suspectedPulmonary congestionLung zonesClinical progressionRothman IndexClinical assessmentDisease severityPatientsPresence of artifactsEvaluate changesLungDetect fluidUltrasound experienceMixed effects modelsScoresDiseaseInterstitial spaceUltrasound systemSTABILITY (Symptomatic Review during Biologic Therapy) of Inflammatory Bowel Disease Patients Receiving Infusion Therapy Improves Clinical Outcomes
Morgan K, Morris J, Cai Q, Kilgore P, Cvek U, Trutschl M, Lofton K, Mavuram M, Ramesh P, Dao N, Alhaque A, Alexander J. STABILITY (Symptomatic Review during Biologic Therapy) of Inflammatory Bowel Disease Patients Receiving Infusion Therapy Improves Clinical Outcomes. Pathophysiology 2024, 31: 398-407. PMID: 39189166, PMCID: PMC11348379, DOI: 10.3390/pathophysiology31030030.Peer-Reviewed Original ResearchInflammatory bowel disease patientsInflammatory bowel diseaseFemale IBD patientsMale CD patientsMale IBD patientsCD patientsUC patientsTherapy visitsIBD patientsDisease severityInfusion therapyFemale UC patientsMale UC patientsRetrospective chart reviewIBD-related symptomsPhysician-patient contactLow disease activityPhysician-patient interviewImprove patient outcomesFemale CD patientsCare gapsImproving clinical outcomesDiagnosis dateMedication changesChronic diseasesIntrinsic link between PGRN and Gba1 D409V mutation dosage in potentiating Gaucher disease
Lin Y, Zhao X, Liou B, Fannin V, Zhang W, Setchell K, Wang X, Pan D, Grabowski G, Liu C, Sun Y. Intrinsic link between PGRN and Gba1 D409V mutation dosage in potentiating Gaucher disease. Human Molecular Genetics 2024, 33: 1771-1788. PMID: 39101473, PMCID: PMC11458007, DOI: 10.1093/hmg/ddae113.Peer-Reviewed Original ResearchGaucher diseaseMutation dosageMouse modelDisease severityProgrammed cell deathRetinal gliosisBrain transcriptomic analysisGD pathogenesisPGRN deficiencyTissue fibrosisDisease progressionGrn-/- miceSevere phenotypeGlycosphingolipid accumulationTranscriptome analysisInflammatory responseGCase functionMiceCell deathShort life spanNeurobehavioral analysisDiseaseGCase activityNeurodegenerative diseasesPGRNFaecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis
Kreimeyer H, Gonzalez C, Fondevila M, Hsu C, Hartmann P, Zhang X, Stärkel P, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Bataller R, Investigators A, Gonzalez D, Schnabl B. Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis. Gut 2024, 74: 103-115. PMID: 39033024, PMCID: PMC11631684, DOI: 10.1136/gutjnl-2024-332730.Peer-Reviewed Original ResearchAlcohol-associated hepatitisShort-term survivalMulticentre cohortSeverity of ALDAlcohol-associated liver diseaseIndependent validation cohortInduce gut dysbiosisNon-invasive markerAlcohol-use disordersNeutrophil degranulationPrediction of short-term survivalPrognostic effectHepatic neutrophilsValidation cohortBacterial translocationNeutrophil granulesMPO levelsLiver diseaseFecal biomarkersTandem mass tagPatientsGut dysbiosisLiver damageDisease severityNeutrophilsBiomarkers of Kidney Disease Progression in ADPKD
Ghanem A, Borghol A, Debeh F, Paul S, AlKhatib B, Harris P, Garimella P, Hanna C, Kline T, Dahl N, Chebib F. Biomarkers of Kidney Disease Progression in ADPKD. Kidney International Reports 2024, 9: 2860-2882. PMID: 39435347, PMCID: PMC11492289, DOI: 10.1016/j.ekir.2024.07.012.Peer-Reviewed Original ResearchAutosomal dominant polycystic kidney diseaseDominant polycystic kidney diseaseKidney disease progressionPolycystic kidney diseaseDisease progressionMonogenic kidney disorderKidney diseaseHeight-adjusted total kidney volumeDisease severityTotal kidney volumePKD1 geneGlomerular filtration rateMayo imaging classificationBody mass indexPersonalized treatment strategiesIncreased kidney sizePathogenic variantsEfficacy of treatmentAssess disease severityTotal cyst volumeGenetic profileImprove patient outcomesPredictive biomarkersCyst volumeKidney volumeSix-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
Lebwohl M, Strober B, Schrader A, Li A, Eckmann T, Zhu B, Malatestinic W, Birt J, Feely M, Blauvelt A. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. Drugs - Real World Outcomes 2024, 11: 451-464. PMID: 38914857, PMCID: PMC11365873, DOI: 10.1007/s40801-024-00439-w.Peer-Reviewed Original ResearchTumor necrosis factor inhibitorsInvestigator's Global AssessmentEffectiveness of ixekizumabDermatology Life Quality IndexDermatology Life Quality Index 0/1Body surface areaIL-23iCorEvitas Psoriasis RegistryIL-12/23iPatient-reported outcomesIL-17iPsoriasis RegistryBiologic therapySkin painSwitching to ixekizumabIL-23 inhibitorsDisease severityInterleukin-23 inhibitorAdjusted mean changesMultivariable modified Poisson regressionInterleukin-12/23 inhibitorsFollow-up visitConfidence intervalsModified Poisson regressionReal-world studyVaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis
Pischel L, Martini B, Yu N, Cacesse D, Tracy M, Kharbanda K, Ahmed N, Patel K, Grimshaw A, Malik A, Goshua G, Omer S. Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis. Vaccine 2024, 42: 126053. PMID: 38906763, DOI: 10.1016/j.vaccine.2024.06.021.Peer-Reviewed Original ResearchPost-exposure prophylaxisMVA-BNVaccine effectivenessMeta-analysisTime of administrationNewcastle-Ottawa ScaleRisk of publication biasMeasuring vaccine efficacyImmortal time biasImmunogenicity studiesNewcastle-OttawaWeb of ScienceVaccine efficacyAnimal studiesEgger's testDisease severityFunnel plotPrimary searchDosePublication biasStudy qualityVaccineSystematic reviewVaccination timingMpox outbreakClinical Characteristics of 427 Unvaccinated Chinese Adult Patients with Maintenance Hemodialysis Infected with the SARS-CoV-2 Omicron Variant: A Retrospective Study
Ha X, Zhao Z, Zhao T, Muhetaer G, Wang X, Bao A, Duan Y, Zhuang J, Song X, Zhou Y, Zhang Q, Wu J, Fan M, Zhang L, Tian X, Jiang H. Clinical Characteristics of 427 Unvaccinated Chinese Adult Patients with Maintenance Hemodialysis Infected with the SARS-CoV-2 Omicron Variant: A Retrospective Study. Integrative Medicine In Nephrology And Andrology 2024, 11: e23-00018. DOI: 10.1097/imna-d-23-00018.Peer-Reviewed Original ResearchSARS-CoV-2 Omicron infectionMaintenance hemodialysisClinical characteristicsMHD patientsSARS-CoV-2 Omicron variantSARS-CoV-2Disease severityFollow-upSerum C-reactive protein levelsOmicron infectionRisk factorsC-reactive protein levelsFollow-up assessmentIndependent risk factorSpectrum of disease severityChinese adult patientsTailored treatment strategiesNegative nucleic acidAdult MHD patientsMaintenance hemodialysis patientsHigh-risk populationArterial oxygen partial pressureOmicron variantProcalcitonin levelsPrognostic factors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply